Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema

Archives of Ophthalmology

Volumn 125, Issue 3, 2007, Pages 309-317

  Kuppermann, Baruch D ^a   Blumenkranz, Mark S ^b   Haller, Julia A ^c   Williams, George A ^d   Weinberg, David V ^e   Chou, Connie ^f   Whitcup, Scott M ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e EYE INSTITUTE   (United States)

^f ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

ADOLESCENT; ADULT; AFTERCATARACT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EYE DISEASE; EYE IRRITATION; EYE PAIN; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; IRVINE GASS SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; SIDE EFFECT; UVEITIS; VISUAL ACUITY; VITREOUS DISEASE; VITREOUS HEMORRHAGE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOCOMPATIBLE MATERIALS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; LACTIC ACID; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; POLYGLYCOLIC ACID; POLYMERS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 33947275043     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.3.309     Document Type: Article

References (30)

1. Ferris FL III, Patz A. Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol. 1984;28(suppl):452-461.
2. Klein R, Klein BE, Moss SE, Cruickshanks K. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV: the long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS report number 4. Int Ophthalmol Clin. 1987;27:265-272.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
5. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-77.
6. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes. 1998;47:1953-1959.
7. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears M, Tarkkanen A, eds. Surgical Pharmacology of the Eye. New York, NY: Raven Press; 1985:83-133.
8. Nauck M, Karakiulakis G, Perruchoud A, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
9. Tennant JL. Cystoid maculopathy: 125 prostaglandins in ophthalmology. In: Emery JM, ed. Current Concepts in Cataract Surgery: Selected Proceedings of the Fifth Biennial Cataract Surgical Congress: Section 3. St Louis, Mo: CV Mosby; 1978:360-362.
10. Antonetti DA, Wolpert EB, Maio L, Harhaj NS, Scaduto RC Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem. 2002;80:667-677.
11. Lee VHL, Pince KJ, Frambach DA, Martini B. Drug delivery to the posterior segment. In: Ogden TE, Schachat AP, eds. Retina. Vol 1. St Louis, Mo: CV Mosby; 1989:483-498.
12. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505-512.
13. Maurice DM. Micropharmaceutics of the eye. Ocular Inflammation Ther. 1983;1:97-102.
14. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61.
15. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. 3-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:2044-2049.
16. Young S, Larkin G, Branley M, Lightmann S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29:2-6.
17. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
18. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004;122:1131-1136.
19. Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol. 1991;15:233-235.
20. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110:259-266.
21. Maxwell DP Jr, Brent BD, Diamond JG, Wu L. Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology. 1991;98:1370-1375.
22. Kobayashi H, Shiraki K, Ikada Y. Toxicity test of biodegradable polymers by implantation in rabbit cornea. J Biomed Mater Res. 1992;26:1463-1476.
23. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci. 1991;32:1785-1790.
24. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50:50 poly(dl-lactide-co-glycolide) microcapsules. J Biomed Mater Res. 1985;19:349-365.
25. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study Design and baseline patient characteristics: ETDRS report number 7. Ophthalmology. 1991;98:741-756.
26. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. Am J Ophthalmol. 2001;131:167-175.
27. Butcher J, Austin M, McGalliard J, Bourke R. Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ. 1994;309:43.
28. Armaly ME. Statistical attributes of the steroid hypertensive response in the clinically normal eye, I: the demonstration of three levels of response. Invest Ophthalmol. 1965;4:187-197.
29. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965;4:198-205.
30. Wingate RJB, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999;27:431-432.